. Author manuscript; available in PMC: 2014 Sep 10.

Published in final edited form as: J Thorac Oncol. 2013 Jul;8(7):823–859. doi: 10.1097/JTO.0b013e318290868f

TABLE 1.

Different Outcomes in All Stages of Non–Small Cell Lung Cancer Patients With and Without EGFR Mutations, Treated With Tyrosine Kinase Inhibitor

	Mean ± SD		Percentage
Outcome	EGFR Mutation Positive	EGFR Mutation Negative	EGFR Mutation Positive	EGFR Mutation Negative	n (N)	WMD (95% CI)	RR (95% CI)	P Value
Response rate, %^a			68	11	51 (3644)		5.16 (4.41–6.04)	<.001
Disease control rate, %^b			86	42	28 (2204)		1.99 (1.73–2.29)	<.001
Time to progression/progression-free survival, moc	12.0±7.86	3.4±2.59			27 (2347)	8.66 (6.31–11.00)		<.001
Median survival time, mod	23.3 ± 18.4	12.1 ± 13.9			27 (2489)	10.66 (8.36–12.96)		<.001

Abbreviations: CI, confidence interval; n, number of studies; N, number of patients; RR, relative risk; SD, standard deviation; WMD, weighted mean difference.

References ^{7, 17, 28, 48, 53, 56, 58, 110, 129, 133, 170, 191–198, 202, 211, 250–278}

References ^{7, 17, 53, 56, 115, 129, 133, 191, 193–195, 202, 250–254, 258, 259, 261, 266, 267, 273–275, 277–279}

References ^{17, 28, 53, 56, 58, 129, 170, 185, 191, 193 , 195, 201, 211, 250–252, 254, 255, 261–263, 266, 267, 275–278}

References ^{17, 28, 53, 56, 90, 129, 170, 183, 184, 191, 193, 197, 253–255, 258, 259, 261, 262, 266, 267, 270–272, 276–278}.